Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Sue Ping Thang; John Violet; Shahneen Sandhu; Amir Iravani; Tim Akhurst; Grace Kong; Aravind Ravi Kumar; Declan G Murphy; Scott G Williams; Rodney J Hicks; Michael S Hofman

Journal article

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Scott G Williams, Rodney J Hicks, Michael S Hofman

EUROPEAN UROLOGY ONCOLOGY | ELSEVIER | Published : 2019

DOI: 10.1016/j.euo.2018.11.007

Abstract

BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and represents a target for imaging and therapy. We undertook a prospective trial of 177Lu-PSMA-617 radioligand therapy in men with high PSMA expression who progressed after standard therapies. OBJECTIVE: To determine outcomes for men screened for the trial but not treated because of low PSMA expression. DESIGN, SETTING, AND PARTICIPANTS: Patients screened with 68Ga-PSMA-11 and 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography in a prospective trial. Patients ineligible for enrolment with low PSMA expression or FDG-positive PSMA-negativ..

View full abstract

University of Melbourne Researchers

Prof Shahneen Sandhu Author

A/Prof Grace Kong Author

A/Prof Aravind Ravi Kumar Author

Prof Declan Murphy Author

Related Projects (1)

MOLECULAR IMAGING AS A CRITICAL TOOL IN DISCOVERY OF THE BASIS OF TUMOUR HETEROGENEITY AND DEVELOPING NOVEL THERAPIES TO OVERCOME THERAPEUTIC RESISTANCE

Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. Howe..

Grants

Funding Acknowledgements

Sue Ping Thang was supported by a Health Manpower Development Programme Award from the Ministry of Health, Singapore during her fellowship at Peter MacCallum Cancer Centre. Michael S. Hofman and Shahneen Sandhu are supported by Clinical Fellowship Awards from the Peter MacCallum Foundation. Michael S. Hofman is supported by a Movember Clinical Trials Award awarded through the Prostate Cancer Foundation of Australia Research Program. Rodney J. Hicks is supported by a National Health and Medical Research Foundation of Australia Practitioner Fellowship. <SUP>177</SUP>Lu (no carrier added) was supplied by the Australian National Nuclear Science and Technology Organisation. PSMA-617 was supplied by Advanced Biochemical Compounds (ABX, Radeberg, Germany) and Endocyte (USA). The study was sponsored by the Peter MacCallum Cancer Centre (Melbourne, Australia). None of the sponsors played a direct role in the study.